XML 17 R9.htm IDEA: XBRL DOCUMENT
v3.24.3

Insider Trading Arrangements | 3 Months Ended
--- | ---
Sep. 30, 2024 shares
Trading Arrangements, by Individual |  |
Material Terms of Trading Arrangement | During the quarter ended September 30, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
|  |  | Character of Trading Arrangement |  |
Name and Title | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares to be Sold | Expiration Date
Faye M. Feller, M.D., Executive Vice President and Chief Medical Officer | Adoption | July 12, 2024 | X |  | 974,167 1 | June 30, 2025
Andrew J. Grethlein, Ph.D., Executive Vice President and Chief Operating Officer | Adoption | July 12, 2024 | X |  | 1,279,985 2 | November 14, 2025
John A. Scarlett, M.D., Chairman of the Board, President and Chief Executive Officer | Adoption | July 12, 2024 | X |  | 1,374,298 3 | July 11, 2025
Anil Kapur Executive Vice President, Corporate Strategy, and Chief Commercial Officer (until August 31, 2024) | Adoption | July 9, 2024 | X |  | 1,587,500 4 | June 27, 2025
* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.
1 Consists of 974,167 shares subject to stock options previously granted by Geron to Dr. Feller. 2 Consists of 1,279,985 shares subject to stock options previously granted by Geron to Dr. Grethlein. 3 Consists of 1,374,298 shares subject to stock options previously granted by Geron to Dr. Scarlett. 4 Mr. Kapur's employment with Geron terminated on August 31, 2024. Consists of 1,587,500 shares subject to stock options previously granted by Geron to Mr. Kapur. |
Faye M. Feller, M.D. |  |
Trading Arrangements, by Individual |  |
Name | Faye M. Feller, M.D. |
Title | Executive Vice President and Chief Medical Officer |
Rule 10b5-1 Arrangement Adopted | true |
Non-Rule 10b5-1 Arrangement Adopted | false |
Adoption Date | July 12, 2024 |
Expiration Date | June 30, 2025 |
Arrangement Duration | 354 days |
Aggregate Available | 974,167 | [1]
Andrew J. Grethlein, Ph.D. |  |
Trading Arrangements, by Individual |  |
Name | Andrew J. Grethlein, Ph.D. |
Title | Executive Vice President and Chief Operating Officer |
Rule 10b5-1 Arrangement Adopted | true |
Non-Rule 10b5-1 Arrangement Adopted | false |
Adoption Date | July 12, 2024 |
Expiration Date | November 14, 2025 |
Arrangement Duration | 491 days |
Aggregate Available | 1,279,985 | [2]
John A. Scarlett, M.D. |  |
Trading Arrangements, by Individual |  |
Name | John A. Scarlett, M.D. |
Title | Chairman of the Board, President and Chief Executive Officer |
Rule 10b5-1 Arrangement Adopted | true |
Non-Rule 10b5-1 Arrangement Adopted | false |
Adoption Date | July 12, 2024 |
Expiration Date | July 11, 2025 |
Arrangement Duration | 365 days |
Aggregate Available | 1,374,298 | [3]
Anil Kapur |  |
Trading Arrangements, by Individual |  |
Name | Anil Kapur |
Title | Executive Vice President, Corporate Strategy, and Chief Commercial Officer |
Rule 10b5-1 Arrangement Adopted | true |
Non-Rule 10b5-1 Arrangement Adopted | false |
Adoption Date | July 9, 2024 |
Expiration Date | June 27, 2025 |
Arrangement Duration | 354 days |
Aggregate Available | 1,587,500 | [4]
[1] | Consists of 974,167 shares subject to stock options previously granted by Geron to Dr. Feller.
[2] | Consists of 1,279,985 shares subject to stock options previously granted by Geron to Dr. Grethlein.
[3] | Consists of 1,374,298 shares subject to stock options previously granted by Geron to Dr. Scarlett.
[4] | Mr. Kapur's employment with Geron terminated on August 31, 2024. Consists of 1,587,500 shares subject to stock options previously granted by Geron to Mr. Kapur.

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details
Name: | ecd_MtrlTermsOfTrdArrTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details
Name: | ecd_NonRule10b51ArrAdoptedFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details
Name: | ecd_Rule10b51ArrAdoptedFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details
Name: | ecd_TradingArrByIndTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details
Name: | ecd_TrdArrAdoptionDate
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details
Name: | ecd_TrdArrDuration
Namespace Prefix: | ecd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details
Name: | ecd_TrdArrExpirationDate
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details
Name: | ecd_TrdArrIndName
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details
Name: | ecd_TrdArrIndTitle
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details
Name: | ecd_TrdArrSecuritiesAggAvailAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ecd_IndividualAxis=gern_FayeMFellerMDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=gern_AndrewJGrethleinPhDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=gern_JohnAScarlettMDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=gern_AnilKapurMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |